Pacira Pharma (PCRX) Tops Q3 EPS by 7c

Pacira Pharma (NASDAQ: PCRX) reported Q3 EPS of $0.72, $0.07 better than the analyst estimate of $0.65. Revenue for the quarter came in at $127.7 million versus the consensus estimate of $130.38 million.

For earnings history and earnings-related data on Pacira Pharma (PCRX) click here.

You May Also Be Interested In

• Oracle reports earnings today: AI spending bet faces its toughest test yet
• Casey's General Stores (CASY) PT Lowered to $720 at UBS on Peak Fuel Margin Concerns
• Driven Brands (DRVN) PT Raised to $18 at Canaccord